Rosetta Genomics, Ltd. (NASDAQ: ROSG) leverages an integrative research platform to develop and commercialize a full range of microRNA-based molecular diagnostics and address critical needs in cancer and other disease areas. Building on its proprietary platform technologies and a strong IP portfolio, the company is working to solve unmet medical needs and improve the lives of patients through a proven combination of diagnostic expertise and therapeutic innovations.
The company’s current product pipeline includes an assortment of unique diagnostic tests for a collection of medical conditions – including thyroid neoplasia, heart failure, kidney rejection and Alzheimer’s disease. In recent months, Rosetta has worked to build on this pipeline and expand its presence in the industry, most notably through the acquisition of PersonalizeDx in April. PersonalizeDx is a rapidly growing molecular diagnostics and services company serving community-based pathologists, urologists, oncologists and other reference laboratories across the United States.
“The acquisition of PersonalizeDx will have wide-ranging, positive financial, commercial, operational and pipeline impact on Rosetta Genomics, and brings with it exceptional talent to complement the industry-leading team at Rosetta Genomics,” stated Kenneth A. Berlin, president and chief executive officer of Rosetta, in a recent news release. “In joining forces with PersonalizeDx, Rosetta Genomics will gain critically important commercial and revenue scale in the marketplace for oncology diagnostics.”
In May, Rosetta built on the momentum gained from its acquisition by releasing OncoGxOne™, the company’s next-generation sequencing panel that detects a vast number of genetic alterations implicated in cancer to provide clear, concise and actionable clinical recommendations from a single, comprehensive test. Moving forward, OncoGxOne™ will compete with currently available genomic profiling offerings through next-generation sequencing platforms that can identify potentially actionable cancer-driving mutations, which can be targeted by specific therapies.
“We look forward to a successful commercial launch for OncoGxOne™ with our recently-expanded sales force and expect that over time it will become an important contributor to our revenues,” concluded Berlin.
Rosetta’s recent efforts have strategically positioned the company to realize significant increases in revenue in the coming years. Based on PersonalizeDx’s 2014 revenue, which was $6.9 million, the company has modified its financial model, leading to forecast revenue of $18.5 million in 2016. For prospective investors, this potential growth could provide the opportunity for significant returns in the future.
For more information, visit www.rosettagenomics.com
